Skip to content
SEC filings edition: Friday, November 13, 2026 · 767 companies with filings Publisher's serviceBoardeon, your AI board · Hire your board →
Monday, November 16, 2026Every business day from SEC EDGAR
SEC EDGAR · Nov 13, 2026 1bankruptcies 11delisting notices 12late filings 43leadership changes 6IPO filings 199private raises 90earnings releases
Company page · CIK 1534248 · CMMB

Chemomab Therapeutics Ltd.

Filing with the SEC SEC-reporting company Tel Aviv, MA Nasdaq
An email when it files something new with the SEC. Your account

What this means

  • Net loss in 2025Net loss of $9M for the year (2024: −$13.9M).

What to do next

Guides from the Companies Daily newsroom, picked for what the register shows.

Financials from XBRL

Calendar-year frame20252024
Net income (loss)−$9M−$13.9M
Total assets$13.8M$17M
Total liabilities$1.5M$3.4M
Stockholders’ equity$12.3M$13.5M
Cash and equivalents$7.6M$6.1M

From XBRL data the company filed with the SEC (data.sec.gov frames, US GAAP, US dollars). A frame aligns the fiscal year with the calendar year closest to it; this company’s fiscal year ends December 31. Check the annual report for the exact figures and periods.

Name as filed
Chemomab Therapeutics Ltd.
Formerly: Anchiano Therapeutics Ltd.
CIK
0001534248
Tickers
CMMB
Kind of filer
SEC-reporting company
Non-accelerated filer; Smaller reporting company
Status
Filing with the SEC
State of incorporation
Israel
Business address
Tel Aviv, Massachusetts
Industry (SIC)
2834 · Pharmaceutical preparations
Industry: D · Manufacturing →
Fiscal year ends
December 31
Last annual report
20-F for the period ended Dec 31, 2025
Last quarterly report
10-Q for the quarter ended Mar 31, 2023
Bankruptcy reported
Not in our data
Last edition event
Nov 10, 2026

Filing history

Newest first: the filings we classify (8-K items, late filing notices, delistings, deregistration, IPO registrations, Schedule 13D, Form D, annual and quarterly reports), from Jan 1, 2023. All documents, including those we do not classify, are in the EDGAR filing index.

  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Nov 10, 2026 · filing · edition of Nov 10, 2026
  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Jul 16, 2026 · filing
  • Annual report (20-F): 20-F for the period ended Dec 31, 2025
    Form 20-F · filed Mar 23, 2026 · filing
  • Annual report (20-F): 20-F for the period ended Dec 31, 2024
    Form 20-F · filed Apr 4, 2025 · filing
  • Private raise (Form D)
    Form D · items 06b · filed Aug 9, 2024 · filing
  • Annual report (20-F): 20-F for the period ended Dec 31, 2023
    Form 20-F · filed Mar 28, 2024 · filing
  • Directors or officers changed
    Form 8-K · items 5.02 · filed Jun 16, 2023 · filing
  • Directors or officers changed
    Form 8-K · items 5.02, 7.01, 9.01 · filed Jun 5, 2023 · filing
  • Quarterly report filed: 10-Q for the quarter ended Mar 31, 2023
    Form 10-Q · filed May 11, 2023 · filing
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed May 11, 2023 · filing
  • Annual report (10-K): 10-K for the period ended Dec 31, 2022
    Form 10-K · filed Mar 20, 2023 · filing
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed Feb 21, 2023 · filing
  • IPO registration filed: Registration statement (S-1)
    Form S-1 · filed Jan 13, 2023 · filing